Next-Generation Antibody Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Next-Generation Antibody Therapeutics market is segmented by Therapeutic Area (Oncology and Autoimmune or Inflammatory), Technology (Antibody-Drug Conjugates, Bispecific Antibodies, Fc-Engineered Antibodies, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD Million) for the above segments.

Next-Generation Antibody Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Next-Generation Antibody Therapeutics Market Size

Next-Generation Antibody Therapeutics Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
CAGR 12.10 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration Medium

Major Players

Next-Generation Antibody Therapeutics Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Next-Generation Antibody Therapeutics Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Next-Generation Antibody Therapeutics Market Analysis

The Next-Generation Antibody Therapeutics Market is expected to register a CAGR of 12.1% during the forecast period.

The COVID-19 outbreak put an immense burden on the healthcare infrastructure to develop advanced treatments and vaccines. Owing to the high specificity and reliability of next-generation antibody therapeutics, monoclonal antibodies (mAbs) emerged as powerful tools to treat and detect numerous diseases, including SARS and CoV-2, which resulted in the evolution of the next-generation antibody therapeutics sector. As per the article published in January 2022 in the Journal of Biomedical Science, many researchers have started to urgently develop antibody-based assays for the detection of SARS-CoV-2 and Ab therapeutics for use as COVID-19 treatment agents. For instance, in September 2022, AstraZeneca's Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination, has been recommended for marketing authorization in the European Union for the treatment of adults and adolescents, aged 12 years and older, weighing at least 40 kg, with COVID19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID19. Hence, the COVID-19 pandemic was anticipated to positively impact the next-generation antibody therapeutics market in the coming years.

The major factor attributing to the growth of the market is the increase in the prevalence of different chronic diseases such as rheumatoid arthritis, inflammatory bowel disorder, Crohn's disease, and cancer. According to the research published by Medscape in January 2022, the annual incidence rate of rheumatoid arthritis is approximately 3 cases per 10,000 people, and the prevalence rate is approximately 1% globally. Furthermore, the American Cancer Society published the statistics in January 2021, estimating more than 1.9 million new cancer cases to be diagnosed and 609,360 cancer deaths in the United States in 2022. Due to their enhanced efficacy, increased safety, and ability to deliver targeted treatment, next-generation antibody therapies are primarily used to treat chronic diseases, including cancer and autoimmune disorders. Thus, it is anticipated that the studied market would expand in a lucrative way due to the rising prevalence of chronic diseases and rare disorders, where next-generation antibodies serve as the predominant therapy.

Leading biotechnology and pharmaceutical corporations are increasingly funding the creation of new therapeutic antibodies to fight inflammatory illnesses, cancer, and autoimmune disorders. For instance, in November 2022, Seagen announced the US Food and Drug Administration's (FDA) approval of a new indication for brentuximab vedotin, ADCETRIS, for children with previously untreated high-risk Hodgkin lymphoma. In November 2022, ImmunoGen announced that the U.S. FDA had granted accelerated approval for ELAHERE (mirvetuximab soravtansine-gynx) for the treatment of platinum-resistant ovarian cancer in adults. Additionally, in July 2022, F-star Therapeutics announced a license agreement to grant Takeda a worldwide, exclusive, royalty-bearing license to research, develop, and commercialize a bispecific next-generation antibody against an immuno-oncology target using F-star's proprietary Fcab and mAb2 platforms. In March 2022, Bayer announced its plans to spend EUR 2 billion over the next three years to expand its next-gen manufacturing capabilities.

Therefore, the studied market is likely to witness growth over the forecast period due to several factors, such as growing advancements in monoclonal antibody technology, rising incidences of chronic disorders, and increasing initiatives for the discovery and development of next-generation antibody therapeutics. However, strict regulations on the approval of these therapeutics, coupled with the inflated costs of the next generation of antibody therapeutics, are expected to hinder market growth during the study period.

Next-Generation Antibody Therapeutics Industry Overview

The market for next-generation antibody therapeutics is moderately competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some prominent players are acquiring other companies to consolidate their market positions across the globe, while others are launching new products. Some of the companies that are currently dominating the market are Amgen Inc., AstraZeneca Plc., Bayer AG, Biogen, Bristol-Myers Squibb Company, GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd., ImmunoGen Inc., Kyowa Hakko Kirin Co., Ltd., Pfizer Inc., Seagen Inc., and Xencor, Inc., among others.

Next-Generation Antibody Therapeutics Market Leaders

  1. AstraZeneca Plc.

  2. Bristol-Myers Squibb Company

  3. F. Hoffmann-La Roche Ltd.

  4. Pfizer, Inc.

  5. Seagen Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Concentration.png
Need More Details on Market Players and Competiters?
Download PDF

Next-Generation Antibody Therapeutics Market News

  • December 2022: Sorrento Therapeutics, Inc. received clearance from the U.S. FDA to initiate clinical trials with its next-generation mRNA (STI-1557) vaccine against SARS-CoV-2 Omicron variants.
  • July 2022: Byondis received biologics license application acceptance from the U.S. FDA for Vic-Trastuzumab Duocarmazine (SYD985), an antibody-drug conjugate, as a treatment for patients with HER2-positive advanced breast cancer.

Next-Generation Antibody Therapeutics Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidence of Cancer
    • 4.2.2 Rising Prevalence of Autoimmune Diseases
    • 4.2.3 Technological Progressions in Antibody Therapeutics
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Framework
    • 4.3.2 High costs of Next-Generation Antibody Therapeutics
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Therapeutic Area
    • 5.1.1 Oncology
    • 5.1.2 Autoimmune/Inflammatory
  • 5.2 By Technology
    • 5.2.1 Antibody-Drug Conjugates (ADCs)
    • 5.2.2 Bispecific Antibodies (BsAbs)
    • 5.2.3 Fc-Engineered Antibodies
    • 5.2.4 Antibody Fragments and Antibody-Like Proteins (AF & ALPs)
    • 5.2.5 Biosimilar Antibody Products
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Amgen Inc.
    • 6.1.2 AstraZeneca Plc.
    • 6.1.3 Bayer AG
    • 6.1.4 Biogen
    • 6.1.5 Bristol-Myers Squibb Company
    • 6.1.6 GlaxoSmithKline Plc.
    • 6.1.7 F. Hoffmann-La Roche Ltd
    • 6.1.8 ImmunoGen Inc.
    • 6.1.9 Kyowa Hakko Kirin Co., Ltd.
    • 6.1.10 Pfizer Inc.
    • 6.1.11 Seagen Inc.
    • 6.1.12 Xencor, Inc.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Next-Generation Antibody Therapeutics Industry Segmentation

As per the scope of the report, next-generation antibody therapies include a new improvised therapeutic antibody based on the modification of the conventional immunoglobulin (Ig) format to create novel drugs for the treatment of various diseases. Next-generation antibodies have been clinically developed to be more specific and often more potent than traditional monoclonal antibodies. The next-generation antibody therapeutics market is segmented by therapeutic area (oncology and autoimmunity or inflammation), technology (antibody-drug conjugates, bispecific antibodies, fc-engineered antibodies, and others), and geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Therapeutic Area Oncology
Autoimmune/Inflammatory
By Technology Antibody-Drug Conjugates (ADCs)
Bispecific Antibodies (BsAbs)
Fc-Engineered Antibodies
Antibody Fragments and Antibody-Like Proteins (AF & ALPs)
Biosimilar Antibody Products
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Next-Generation Antibody Therapeutics Market Research FAQs

What is the current Next-Generation Antibody Therapeutics Market size?

The Next-Generation Antibody Therapeutics Market is projected to register a CAGR of 12.1% during the forecast period (2025-2030)

Who are the key players in Next-Generation Antibody Therapeutics Market?

AstraZeneca Plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Pfizer, Inc. and Seagen Inc. are the major companies operating in the Next-Generation Antibody Therapeutics Market.

Which is the fastest growing region in Next-Generation Antibody Therapeutics Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Next-Generation Antibody Therapeutics Market?

In 2025, the North America accounts for the largest market share in Next-Generation Antibody Therapeutics Market.

What years does this Next-Generation Antibody Therapeutics Market cover?

The report covers the Next-Generation Antibody Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Next-Generation Antibody Therapeutics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Next-Generation Antibody Therapeutics Industry Report

Statistics for the 2025 Next-Generation Antibody Therapeutics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Next-Generation Antibody Therapeutics analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.